A Phase 1/2 interventional study of ASTX727 Dose Escalation and ASTX727 Dose Confirmation in Myelodysplastic Syndrome and MDS, sponsored by Astex Pharmaceuticals, Inc.. Completed at 17 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-27.
Sponsored by Astex Pharmaceuticals, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies testing decitabine in Myelodysplastic Syndromes — 9 open to participants now, 16 under way, 1 of them phase 3. Decitabine · Myelodysplastic Syndromes.
Among the 75 studies testing decitabine in Myelodysplastic Syndromes, this one is the 12th largest by enrollment of the 74 interventional ones that give a count, is one of 4 that started in 2014, is one of 10 in phase 1/2, and was the 45th registered.
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.
Browse Myelodysplastic Syndromes studies →9 of the 75 studies testing decitabine in Myelodysplastic Syndromes are open now, in 3 countries. Recruiting first, the newest first:
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+ · Healthy volunteers
West Virginia University · Sites in United States
Ages 18+
Beijing 302 Hospital · Sites in China
Ages 18–70
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 60+
Clinical Hub for Interventional Research (CHOIR) · Sites in Australia
Ages 18+
By country, each count listing its studies:
Decitabine: first FDA approval 2006 (DACOGEN), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 49 · Phase 3 6 · Phase 4 3
First in 1995; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 130 is above the median of 40 across 1,611 interventional studies indexed under Myelodysplastic Syndromes.
Median enrollment 43 across the 74 interventional studies. Of the 48 that completed or were terminated, 29 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 75 have an industry lead sponsor. The 10 most frequent:
This study is registered under Astex Pharmaceuticals, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Astex Pharmaceuticals, Inc. is the lead sponsor of 45 studies on the registry; none are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 6 (46%) have results posted.
17 studies in Myelodysplastic Syndromes by Otsuka Holdings Co., Ltd.: 5 open now, 7 under way, 2 of them phase 3. Of 10 finished, 4 (40%) have results posted.
Among the 17 studies in Myelodysplastic Syndromes by Otsuka Holdings Co., Ltd., this one is the 7th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2014, is one of 4 in phase 1/2, and was the 3rd registered.
Otsuka Holdings Co., Ltd.’s Myelodysplastic Syndromes studies by the year they started, since 2001.
2 of the studies testing decitabine in Myelodysplastic Syndromes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06923488West Virginia UniversityLeflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory Myelodysplastic Syndromes | 2027-10 |
| NCT04282187University of WashingtonDecitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms | 2027-11-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 75 studies testing decitabine in Myelodysplastic Syndromes, from their registry updates:
Among Otsuka Holdings Co., Ltd.’s 17 in Myelodysplastic Syndromes:
This tab as a report to print or save as PDF → With an account.
This first-in-human, 3-stage, open-label study evaluated the safety and pharmacokinetics of ASTX727, as well as determined the dose for later stages.
The trial was designed to define daily doses of the individual components (cedazuridine [E7727] or decitabine) so that decitabine exposure after oral administration would be comparable to exposure after IV decitabine at the approved daily dose of 20 mg/m\^2. The main objective of Phases 1 and 2 was to establish and confirm the doses of the 2 components to be used in the final fixed-dose combination (FDC) product (ASTX727) using mainly pharmacokinetics and pharmacodynamics as endpoints.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Starting cohort was administered 40 mg oral cedazuridine and 20 mg oral decitabine. Participants were enrolled into successive cohorts in which either the cedazuridine or decitabine oral dose was varied in Course 1 Day 2 through Course 1 Day 5 for comparison with a single dose of IV decitabine at 20 mg/m\^2 administered on Day 1 by continuous IV infusion over 1 hour (28 days per course).
Drug: ASTX727 Dose Escalation
Participants were randomized in a 1:1 ratio to receive either oral cedazuridine (E7727) (100 mg) + decitabine (35 mg) capsules Dailyx5 in Course 1 followed by IV decitabine (20 mg/m\^2) Dailyx5 in Course 2 (28 days per course) or the converse. In Courses ≥ 3, participants received cedazuridine and decitabine capsules Dailyx5 in 28-day courses until disease progression, unacceptable toxicity, withdrawal of consent or withdrawal from the study.
Drug: ASTX727 Dose Confirmation
Participants were randomized in a 1:1 ratio to receive either the fixed-dose combination (FDC) tablet (100 mg cedazuridine (E7727)/35 mg decitabine) Dailyx5 in Course 1 followed by IV decitabine (20 mg/m\^2) Dailyx5 in Course 2 (28 days per course) or the converse. In Courses ≥ 3, all participants received the FDC tablet Dailyx5 in 28-day courses until disease progression, unacceptable toxicity, withdrawal of consent or withdrawal from the study.
Drug: ASTX727 Fixed-Dose Combination
Oral investigational product and approved IV decitabine
Also known as: cedazuridine (E7727), oral decitabine, IV decitabine
Randomization cross over design for courses 1 and 2
Also known as: ASTX727 oral (combination of oral E7727 and oral decitabine), IV decitabine
Fixed-dose investigational product
Also known as: ASTX727 oral (combination of oral E7727 and oral decitabine)
Mean Decitabine Area Under the Concentration Versus Time Curve (AUC0-t) on Day 5 by Cohort in Phase 1
Mean AUC0-t of oral decitabine given with cedazuridine (E7727) following IV decitabine 20 mg/m\^2 infusion on Day 5. AUCs were calculated by the linear up/log down method using the measured concentration-time values above the BQL (below the limit of quantification).
Time frame: Day 5
Mean Decitabine Area Under the Plasma Concentration Versus Time Curve Ratio (5-day AUC0-t) in Phase 2
Decitabine 5-day AUC ratio following IV decitabine 20 mg/m\^2 infusion versus concomitant oral administration of decitabine + cedazuridine (E7727) or ASTX727 in the dose combination and fixed-dose combination stages, respectively. AUC0-t (the area under the concentration-time curve from time zero to the time of the last (tlast) quantifiable concentration (Ct)) by dose/cohort and course/days was used for estimating decitabine cumulative 5-day AUC0-t exposures.
Time frame: Pre-dose to Day 5
Number of Participants With Dose-limiting Toxicity in Phase 1
Number of participants with protocol-specified dose-limiting toxicities (DLTs) in the dose escalation stage. DLTs were defined using the Common Terminology Criteria for Adverse Events Version 4.0 (CTCAEv4.0), specifically ≥ Grade 3 non-hematologic toxicity (except Grade 3 nausea, vomiting, or diarrhea that is controllable by anti-emetics or optimal therapy or related to underlying disease or disease progression), specific Grade 3 laboratory tests, related prolonged Grade 4 thrombocytopenia or neutropenia that was not present prior to dosing, does not resolve within 14 days, and is not related to underlying disease, or any toxicity related to study treatment that results in treatment delays of \>4 weeks after Day 28.
Time frame: Up to Day 28 in Course 1 (28 days per course)
Mean Maximum %LINE Demethylation in Phase 2
Mean maximum % long interspread nuclear element-1 (LINE-1) demethylation after oral decitabine + cedazuridine (E7727) or ASTX727 (Course 1 or Course 2 - Treatment) compared with IV decitabine 20 mg/m\^2 (Course 1 or Course 2 - IV Decitabine) in the dose confirmation and fixed-dose combination stages, respectively. Least squares mean of maximum %LINE-1 methylation change from baseline.
Time frame: Pre-dose to Day 28 in Course 2 (28 days per course)
Number of Participants With Overall Response in Phase 2
The evaluation of response was based on International Working Group (IWG) 2006 MDS Response Criteria, with overall response calculated as number of participants with complete response+partial response+marrow complete response+hematological improvement (CR+PR+mCR+HI).
Time frame: Up to approximately 29 months
Area Under the Concentration Versus Time Curve of Cedazuridine (E7727) and Cedazuridine-epimer
AUC is a measure of the plasma concentration of the drug over time (AUC0-8). PK parameters are reported for the dose escalation stage by cohort in Phase 1 and dose confirmation and fixed-dose combination stages in Phase 2.
Time frame: At specified timepoints from 0 to 24 hours post-dose
Maximum Observed Plasma Concentration (Cmax) of Cedazuridine (E7727) and Cedazuridine-epimer
Cmax is the maximum observed plasma concentration. PK parameters are reported for the dose escalation stage by cohort in Phase 1 and dose confirmation and fixed-dose combination stages in Phase 2.
Time frame: At specific timepoints from 0 to 24 hours post-dose
Time to Maximum Observed Plasma Concentration (Tmax) of Cedazuridine (E7727) and Cedazuridine-epimer
Tmax is the time to maximum observed plasma concentration. PK parameters are reported for the dose escalation stage by cohort in Phase 1 and the dose confirmation and fixed-dose combination stages in Phase 2.
Time frame: At specific timepoints from 0 to 24 hours post-dose
Maximum Observed Plasma Concentration (Cmax) of Decitabine
Cmax is the maximum observed plasma concentration. PK parameters for plasma decitabine are reported for the dose escalation stage by cohort in Phase 1 and dose confirmation and fixed-dose combination stages in Phase 2.
Time frame: At specific timepoints from 0 to 24 hours post-dose
Time to Maximum Observed Plasma Concentration (Tmax) of Decitabine in Phase 2
Tmax is the time to reach maximum plasma concentration for decitabine. PK parameters for plasma decitabine are reported for the dose confirmation and fixed-dose combination stages.
Time frame: At specific timepoints from 0 to 24 hours post-dose
Duration of Complete Response in Phase 1
Duration of response (in number of days) was calculated from the first time the response was observed to time of relapse or last time point in the study.
Time frame: Up to 32 Months
Duration of Complete Response in Phase 2 - Kaplan-Meier Estimate
Duration of response (in number of days) was calculated from the first time the response was observed to time of relapse or last time point in the study. Kaplan-Meier estimate for complete response is shown.
Time frame: Up to approximately 29 months
Mean Maximum %LINE Demethylation in Phase 1
Mean maximum % long interspread nuclear element-1 (LINE-1) demethylation decrease from baseline after oral decitabine + cedazuridine (E7727) or ASTX727 compared with IV decitabine 20 mg/m\^2 in the dose escalation stage.
Time frame: Pre-dose to Day 28 in Course 2 (28 days per course)
Number of Participants With Overall Response in Phase 1
The evaluation of response was based on International Working Group 2006 MDS Response Criteria, with overall response calculated as number of participants with complete response+partial response+marrow complete response+hematological improvement (CR+PR+mCR+HI).
Time frame: Up to 32 months
Number of Participants With Adverse Events
Number of participants with any treatment-emergent adverse event (AE) and any AE graded ≥3 using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
Time frame: Up to 5 years
Number of Participants With Hematological Improvement
Hematological improvement was calculated as defined by the IWG 2006 MDS Response Criteria.
Time frame: Up to 32 months
Number of Participants With Transfusion Independence
Transfusion independence was calculated based on the number of transfusion-dependent participants at baseline who had no red blood cell or platelet transfusions for 56 consecutive days or more after treatment.
Time frame: Up to 32 months
Number of Participants to Reach Acute Myeloid Leukemia (AML) or Death
Number of participants to reach the event (AML or death), where time to reach AML was calculated as the number of days from the day the participant received the first dose of IV decitabine, oral decitabine + E7727, or the FDC tablet to the date of death or the date of MDS progression to AML as defined by ≥20% blasts in bone marrow or peripheral blood using the World Health Organization classification. Time to AML or death was censored on the last date of contact if a participant was lost to follow up prior to reaching a time-to-event endpoint.
Time frame: Up to 32 months
Number of Participants With Overall Survival
Overall survival was defined as the number of days from the day the participant received the first dose of IV decitabine, oral decitabine + E7727, or the FDC tablet to the date of death, regardless of cause.
Time frame: Up to 32 months
In Phase 1, 127 participants were screened and 44 were randomized and received at least one treatment. In Phase 2, a total of 138 were screened, 86 were randomized, and 80 received at least one treatment.
| Milestone | Phase 1 Dose Escalation Cohort 1 | Phase 1 Dose Escalation Cohort 2 | Phase 1 Dose Escalation Cohort 3 | Phase 1 Dose Escalation Cohort 4 | Phase 1 Dose Escalation Cohort 5 | Phase 2 Dose Confirmation Sequence A | Phase 2 Dose Confirmation Sequence B | Phase 2 Fixed-Dose Combination Sequence A | Phase 2 Fixed-Dose Combination Sequence B |
|---|---|---|---|---|---|---|---|---|---|
| Started | 7 | 6 | 6 | 6 | 19 | 25 | 25 | 16 | 14 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 7 | 6 | 6 | 6 | 19 | 25 | 25 | 16 | 14 |
| Withdrew: Adverse event | 0 | 0 | 1 | 1 | 2 | 1 | 0 | 0 | 0 |
| Withdrew: Death | 2 | 2 | 1 | 1 | 5 | 15 | 14 | 10 | 11 |
| Withdrew: Progressive disease | 2 | 1 | 2 | 0 | 9 | 1 | 2 | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 0 | 0 | 4 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Other | 1 | 3 | 2 | 0 | 3 | 8 | 8 | 4 | 2 |
Mean AUC0-t of oral decitabine given with cedazuridine (E7727) following IV decitabine 20 mg/m\^2 infusion on Day 5. AUCs were calculated by the linear up/log down method using the measured concentration-time values above the BQL (below the limit of quantification).
| ng*h/mL | Phase 1 Dose Escalation Cohort 1 | Phase 1 Dose Escalation Cohort 2 | Phase 1 Dose Escalation Cohort 3 | Phase 1 Dose Escalation Cohort 4 | Phase 1 Dose Escalation Cohort 5 |
|---|---|---|---|---|---|
| Mean Decitabine Area Under the Concentration Versus Time Curve (AUC0-t) on Day 5 by Cohort in Phase 1 | 53.6 ± 40 | 68.9 ± 44 | 94.8 ± 46 | 221 ± 74 | 146 ± 50 |
Decitabine 5-day AUC ratio following IV decitabine 20 mg/m\^2 infusion versus concomitant oral administration of decitabine + cedazuridine (E7727) or ASTX727 in the dose combination and fixed-dose combination stages, respectively. AUC0-t (the area under the concentration-time curve from time zero to the time of the last (tlast) quantifiable concentration (Ct)) by dose/cohort and course/days was used for estimating decitabine cumulative 5-day AUC0-t exposures.
| Ratio of Geometric LSM | Phase 2 Dose Confirmation | Phase 2 Fixed-Dose Combination |
|---|---|---|
| Mean Decitabine Area Under the Plasma Concentration Versus Time Curve Ratio (5-day AUC0-t) in Phase 2 | 93.52 (82.10 to 106.50) | 97.59 (80.48 to 118.30) |
Number of participants with protocol-specified dose-limiting toxicities (DLTs) in the dose escalation stage. DLTs were defined using the Common Terminology Criteria for Adverse Events Version 4.0 (CTCAEv4.0), specifically ≥ Grade 3 non-hematologic toxicity (except Grade 3 nausea, vomiting, or diarrhea that is controllable by anti-emetics or optimal therapy or related to underlying disease or disease progression), specific Grade 3 laboratory tests, related prolonged Grade 4 thrombocytopenia or neutropenia that was not present prior to dosing, does not resolve within 14 days, and is not related to underlying disease, or any toxicity related to study treatment that results in treatment delays of \>4 weeks after Day 28.
| Participants | Phase 1 Dose Escalation Cohort 1 | Phase 1 Dose Escalation Cohort 2 | Phase 1 Dose Escalation Cohort 3 | Phase 1 Dose Escalation Cohort 4 | Phase 1 Dose Escalation Cohort 5 |
|---|---|---|---|---|---|
| Number of Participants With Dose-limiting Toxicity in Phase 1 | 0 | 0 | 0 | 0 | 1 |
Mean maximum % long interspread nuclear element-1 (LINE-1) demethylation after oral decitabine + cedazuridine (E7727) or ASTX727 (Course 1 or Course 2 - Treatment) compared with IV decitabine 20 mg/m\^2 (Course 1 or Course 2 - IV Decitabine) in the dose confirmation and fixed-dose combination stages, respectively. Least squares mean of maximum %LINE-1 methylation change from baseline.
| Percent | Phase 2 Dose Confirmation | Phase 2 Fixed-Dose Combination |
|---|---|---|
| Course 1 - Treatment | 11.159 (9.023 to 13.294) | 10.077 (7.696 to 12.459) |
| Course 1 - IV Decitabine | 11.303 (9.167 to 13.439) | 12.665 (10.12 to 15.211) |
| Course 2 - Treatment | 9.833 (7.446 to 12.219) | 8.134 (4.438 to 11.830) |
| Course 2 - IV Decitabine | 9.920 (7.534 to 12.307) | 8.230 (4.887 to 11.574) |
The evaluation of response was based on International Working Group (IWG) 2006 MDS Response Criteria, with overall response calculated as number of participants with complete response+partial response+marrow complete response+hematological improvement (CR+PR+mCR+HI).
| Participants | Phase 2 Dose Confirmation | Phase 2 Fixed-Dose Combination |
|---|---|---|
| Number of Participants With Overall Response in Phase 2 | 29 | 19 |
AUC is a measure of the plasma concentration of the drug over time (AUC0-8). PK parameters are reported for the dose escalation stage by cohort in Phase 1 and dose confirmation and fixed-dose combination stages in Phase 2.
| ng*h/mL | Phase 1 Dose Escalation Cohort 1 | Phase 1 Dose Escalation Cohort 2 | Phase 1 Dose Escalation Cohort 3 | Phase 1 Dose Escalation Cohort 4 | Phase 1 Dose Escalation Cohort 5 | Phase 2 Dose Confirmation | Phase 2 Fixed-Dose Combination |
|---|---|---|---|---|---|---|---|
| Cedazuridine | 1650 ± 43 | 1990 ± 64 | 3190 ± 53 | 4830 ± 51 | 3490 ± 46 | 2370 ± 56.8 | 1510 ± 49.4 |
| Cedazuridine-epimer | 503 ± 20 | 917 ± 64 | 1670 ± 48 | 2180 ± 34 | 1560 ± 56 | 1190 ± 48.3 | 710 ± 38 |
Cmax is the maximum observed plasma concentration. PK parameters are reported for the dose escalation stage by cohort in Phase 1 and dose confirmation and fixed-dose combination stages in Phase 2.
| ng/mL | Phase 1 Dose Escalation Cohort 1 | Phase 1 Dose Escalation Cohort 2 | Phase 1 Dose Escalation Cohort 3 | Phase 1 Dose Escalation Cohort 4 | Phase 1 Dose Escalation Cohort 5 | Phase 2 Dose Confirmation | Phase 2 Fixed-Dose Combination |
|---|---|---|---|---|---|---|---|
| Cedazuridine | 309 ± 50 | 376 ± 67 | 636 ± 50 | 697 ± 75 | 570 ± 51 | 451 ± 51.4 | 293 ± 43.1 |
| Cedazuridine-epimer | 96 ± 22 | 184 ± 70 | 343 ± 44 | 321 ± 47 | 291 ± 54 | 235 ± 49 | 154 ± 44.6 |
Tmax is the time to maximum observed plasma concentration. PK parameters are reported for the dose escalation stage by cohort in Phase 1 and the dose confirmation and fixed-dose combination stages in Phase 2.
| hours | Phase 1 Dose Escalation Cohort 1 | Phase 1 Dose Escalation Cohort 2 | Phase 1 Dose Escalation Cohort 3 | Phase 1 Dose Escalation Cohort 4 | Phase 1 Dose Escalation Cohort 5 | Phase 2 Dose Confirmation | Phase 2 Fixed-Dose Combination |
|---|---|---|---|---|---|---|---|
| Cedazuridine | 3 (2 to 4) | 3 (2 to 4) | 3 (3 to 4) | 3 (2 to 6) | 3 (2 to 6) | 3 (1.50 to 4.08) | 3 (2.00 to 7.18) |
| Cedazuridine-epimer | 3 (2 to 4) | 3 (2 to 3) | 3 (3 to 4) | 3 (2 to 6) | 3 (2 to 6) | 3 (1.50 to 6.17) | 3.05 (2.00 to 7.20) |
Cmax is the maximum observed plasma concentration. PK parameters for plasma decitabine are reported for the dose escalation stage by cohort in Phase 1 and dose confirmation and fixed-dose combination stages in Phase 2.
| ng/mL | Phase 1 Dose Escalation Cohort 1 | Phase 1 Dose Escalation Cohort 2 | Phase 1 Dose Escalation Cohort 3 | Phase 1 Dose Escalation Cohort 4 | Phase 1 Dose Escalation Cohort 5 | Phase 2 Dose Confirmation | Phase 2 Fixed-Dose Combination |
|---|---|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Decitabine | 54.0 ± 36 | 76.5 ± 42 | 80.9 ± 41 | 161 ± 51 | 138 ± 55 | 126 ± 70.9 | 126 ± 76.2 |
Tmax is the time to reach maximum plasma concentration for decitabine. PK parameters for plasma decitabine are reported for the dose confirmation and fixed-dose combination stages.
| hours | Phase 2 Dose Confirmation | Phase 2 Fixed-Dose Combination |
|---|---|---|
| Time to Maximum Observed Plasma Concentration (Tmax) of Decitabine in Phase 2 | 1.00 (0.47 to 3.00) | 0.95 (0.47 to 2.12) |
Duration of response (in number of days) was calculated from the first time the response was observed to time of relapse or last time point in the study.
| days | Phase 1 Dose Escalation Cohort 1 | Phase 1 Dose Escalation Cohort 2 | Phase 1 Dose Escalation Cohort 3 | Phase 1 Dose Escalation Cohort 4 | Phase 1 Dose Escalation Cohort 5 |
|---|---|---|---|---|---|
| Duration of Complete Response in Phase 1 | 546.00 (546.0 to 546.0) | 364.00 (56.0 to 672.0) | 470.00 (470.0 to 470.0) | 29.00 (29.0 to 29.0) | 399.0 (202.0 to 420.0) |
Duration of response (in number of days) was calculated from the first time the response was observed to time of relapse or last time point in the study. Kaplan-Meier estimate for complete response is shown.
| days | Phase 2 Dose Confirmation | Phase 2 Fixed-Dose Combination |
|---|---|---|
| Duration of Complete Response in Phase 2 - Kaplan-Meier Estimate | 413.0 (180.0 to 553.0) | 155.0 (35.0 to 285.0) |
Mean maximum % long interspread nuclear element-1 (LINE-1) demethylation decrease from baseline after oral decitabine + cedazuridine (E7727) or ASTX727 compared with IV decitabine 20 mg/m\^2 in the dose escalation stage.
| Percent change | Phase 1 Dose Escalation Cohort 1 | Phase 1 Dose Escalation Cohort 2 | Phase 1 Dose Escalation Cohort 3 | Phase 1 Dose Escalation Cohort 4 | Phase 1 Dose Escalation Cohort 5 |
|---|---|---|---|---|---|
| Course 1 | -8.3 ± 5.28 | -9.2 ± 5.84 | -10.5 ± 7.55 | -12.1 ± 7.82 | -11.7 ± 5.67 |
| Course 2 | -8.0 ± 3.56 | -7.1 ± 2.92 | -8.9 ± 5.42 | -8.6 ± 3.24 | -7.5 ± 5.47 |
The evaluation of response was based on International Working Group 2006 MDS Response Criteria, with overall response calculated as number of participants with complete response+partial response+marrow complete response+hematological improvement (CR+PR+mCR+HI).
| Participants | Phase 1 Dose Escalation Cohort 1 | Phase 1 Dose Escalation Cohort 2 | Phase 1 Dose Escalation Cohort 3 | Phase 1 Dose Escalation Cohort 4 | Phase 1 Dose Escalation Cohort 5 |
|---|---|---|---|---|---|
| Number of Participants With Overall Response in Phase 1 | 4 | 3 | 2 | 1 | 3 |
Number of participants with any treatment-emergent adverse event (AE) and any AE graded ≥3 using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
| Participants | Phase 1 Dose Escalation Cohort 1 | Phase 1 Dose Escalation Cohort 2 | Phase 1 Dose Escalation Cohort 3 | Phase 1 Dose Escalation Cohort 4 | Phase 1 Dose Escalation Cohort 5 | Phase 2 Dose Confirmation | Phase 2 Fixed-Dose Combination |
|---|---|---|---|---|---|---|---|
| Any Adverse Event | 6 | 6 | 6 | 6 | 19 | 50 | 30 |
| Any Grade ≥3 Adverse Event | 5 | 6 | 5 | 6 | 18 | 48 | 28 |
Hematological improvement was calculated as defined by the IWG 2006 MDS Response Criteria.
| Participants | Phase 1 Dose Escalation Cohort 1 | Phase 1 Dose Escalation Cohort 2 | Phase 1 Dose Escalation Cohort 3 | Phase 1 Dose Escalation Cohort 4 | Phase 1 Dose Escalation Cohort 5 | Phase 2 Dose Confirmation | Phase 2 Fixed-Dose Combination |
|---|---|---|---|---|---|---|---|
| Number of Participants With Hematological Improvement | 4 | 3 | 2 | 0 | 3 | 8 | 7 |
Transfusion independence was calculated based on the number of transfusion-dependent participants at baseline who had no red blood cell or platelet transfusions for 56 consecutive days or more after treatment.
| Participants | Phase 1 Dose Escalation Cohort 1 | Phase 1 Dose Escalation Cohort 2 | Phase 1 Dose Escalation Cohort 3 | Phase 1 Dose Escalation Cohort 4 | Phase 1 Dose Escalation Cohort 5 | Phase 2 Dose Confirmation | Phase 2 Fixed-Dose Combination |
|---|---|---|---|---|---|---|---|
| Red Blood Cell | 2 | 0 | 3 | 0 | 2 | 11 | 8 |
| Platelet | 0 | 0 | 1 | 0 | 1 | 3 | 3 |
Number of participants to reach the event (AML or death), where time to reach AML was calculated as the number of days from the day the participant received the first dose of IV decitabine, oral decitabine + E7727, or the FDC tablet to the date of death or the date of MDS progression to AML as defined by ≥20% blasts in bone marrow or peripheral blood using the World Health Organization classification. Time to AML or death was censored on the last date of contact if a participant was lost to follow up prior to reaching a time-to-event endpoint.
| Participants | Phase 1 Dose Escalation Cohort 1 | Phase 1 Dose Escalation Cohort 2 | Phase 1 Dose Escalation Cohort 3 | Phase 1 Dose Escalation Cohort 4 | Phase 1 Dose Escalation Cohort 5 | Phase 2 Dose Confirmation | Phase 2 Fixed-Dose Combination |
|---|---|---|---|---|---|---|---|
| Censored | 4 | 5 | 6 | 5 | 11 | 22 | 11 |
| Event | 3 | 1 | 0 | 1 | 8 | 28 | 19 |
Overall survival was defined as the number of days from the day the participant received the first dose of IV decitabine, oral decitabine + E7727, or the FDC tablet to the date of death, regardless of cause.
| Participants | Phase 1 Dose Escalation Cohort 1 | Phase 1 Dose Escalation Cohort 2 | Phase 1 Dose Escalation Cohort 3 | Phase 1 Dose Escalation Cohort 4 | Phase 1 Dose Escalation Cohort 5 | Phase 2 Dose Confirmation | Phase 2 Fixed-Dose Combination |
|---|---|---|---|---|---|---|---|
| Censored | 6 | 5 | 6 | 5 | 15 | 26 | 14 |
| Event | 1 | 1 | 0 | 1 | 4 | 24 | 16 |
Collected over Up to 5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1 Dose Escalation Cohort 1 | 2/7 (28.6%) | 2/7 (28.6%) | 6/7 (85.7%) |
| Phase 1 Dose Escalation Cohort 2 | 2/6 (33.3%) | 4/6 (66.7%) | 6/6 (100%) |
| Phase 1 Dose Escalation Cohort 3 | 1/6 (16.7%) | 2/6 (33.3%) | 6/6 (100%) |
| Phase 1 Dose Escalation Cohort 4 | 1/6 (16.7%) | 6/6 (100%) | 6/6 (100%) |
| Phase 1 Dose Escalation Cohort 5 | 5/19 (26.3%) | 14/19 (73.7%) | 18/19 (94.7%) |
| Phase 2 Dose Confirmation | 29/50 (58%) | 39/50 (78%) | 48/50 (96%) |
| Phase 2 Fixed-Dose Combination | 21/30 (70%) | 25/30 (83.3%) | 30/30 (100%) |
| Event | Phase 1 Dose Escalation Cohort 1 | Phase 1 Dose Escalation Cohort 2 | Phase 1 Dose Escalation Cohort 3 | Phase 1 Dose Escalation Cohort 4 | Phase 1 Dose Escalation Cohort 5 | Phase 2 Dose Confirmation | Phase 2 Fixed-Dose Combination |
|---|---|---|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 1/7 | 1/6 | 1/6 | 2/6 | 2/19 | 17/50 | 7/30 |
| PneumoniaInfections and infestations | 0/7 | 1/6 | 0/6 | 2/6 | 3/19 | 8/50 | 5/30 |
| SepsisInfections and infestations | 0/7 | 0/6 | 0/6 | 2/6 | 2/19 | 5/50 | 8/30 |
| AnemiaBlood and lymphatic system disorders | 0/7 | 0/6 | 1/6 | 0/6 | 1/19 | 1/50 | 0/30 |
| Abdominal painGastrointestinal disorders | 0/7 | 1/6 | 0/6 | 0/6 | 0/19 | 1/50 | 0/30 |
| Gastrointestinal hemorrhageGastrointestinal disorders | 0/7 | 0/6 | 1/6 | 0/6 | 0/19 | 2/50 | 1/30 |
| DiarrheaGastrointestinal disorders | 0/7 | 1/6 | 0/6 | 0/6 | 1/19 | 0/50 | 0/30 |
| Multiple organ dysfunction syndromeGeneral disorders | 0/7 | 1/6 | 0/6 | 0/6 | 0/19 | 0/50 | 1/30 |
| PyrexiaGeneral disorders | 0/7 | 0/6 | 0/6 | 1/6 | 0/19 | 3/50 | 1/30 |
| BacteremiaInfections and infestations | 0/7 | 0/6 | 0/6 | 1/6 | 1/19 | 3/50 | 0/30 |
| Event | Phase 1 Dose Escalation Cohort 1 | Phase 1 Dose Escalation Cohort 2 | Phase 1 Dose Escalation Cohort 3 | Phase 1 Dose Escalation Cohort 4 | Phase 1 Dose Escalation Cohort 5 | Phase 2 Dose Confirmation | Phase 2 Fixed-Dose Combination |
|---|---|---|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 2/7 | 5/6 | 1/6 | 2/6 | 7/19 | 17/50 | 12/30 |
| FatigueGeneral disorders | 2/7 | 5/6 | 3/6 | 5/6 | 6/19 | 23/50 | 12/30 |
| ThrombocytopeniaBlood and lymphatic system disorders | 4/7 | 3/6 | 4/6 | 3/6 | 10/19 | 27/50 | 15/30 |
| NeutropeniaBlood and lymphatic system disorders | 3/7 | 2/6 | 4/6 | 1/6 | 6/19 | 28/50 | 12/30 |
| NauseaGastrointestinal disorders | 1/7 | 4/6 | 3/6 | 3/6 | 5/19 | 13/50 | 14/30 |
| AnemiaBlood and lymphatic system disorders | 4/7 | 1/6 | 2/6 | 3/6 | 5/19 | 16/50 | 8/30 |
| Abdominal painGastrointestinal disorders | 0/7 | 0/6 | 1/6 | 3/6 | 2/19 | 3/50 | 3/30 |
| Edema peripheralGeneral disorders | 0/7 | 3/6 | 1/6 | 2/6 | 4/19 | 13/50 | 3/30 |
| HypomagnesemiaMetabolism and nutrition disorders | 2/7 | 1/6 | 1/6 | 3/6 | 2/19 | 12/50 | 5/30 |
| Acute kidney injuryRenal and urinary disorders | 0/7 | 3/6 | 0/6 | 1/6 | 2/19 | 2/50 | 3/30 |
Demographic and baseline characteristics are shown for participants who received at least one dose of study drug.
| Age, Continuous(years) | Phase 1 Dose Escalation Cohort 1 | Phase 1 Dose Escalation Cohort 2 | Phase 1 Dose Escalation Cohort 3 | Phase 1 Dose Escalation Cohort 4 | Phase 1 Dose Escalation Cohort 5 | Phase 2 Dose Confirmation | Phase 2 Fixed-Dose Combination | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 69.6 ± 8.1 | 72 ± 6.2 | 74 ± 4.8 | 75.2 ± 7.1 | 71.6 ± 8.8 | 69.7 ± 10.72 | 69.6 ± 10.57 | 70.6 ± 9.67 |
| Sex: Female, Male(Participants) | Phase 1 Dose Escalation Cohort 1 | Phase 1 Dose Escalation Cohort 2 | Phase 1 Dose Escalation Cohort 3 | Phase 1 Dose Escalation Cohort 4 | Phase 1 Dose Escalation Cohort 5 | Phase 2 Dose Confirmation | Phase 2 Fixed-Dose Combination | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 4 | 1 | 3 | 2 | 4 | 9 | 10 | 33 |
| Male | 3 | 5 | 3 | 4 | 15 | 41 | 20 | 91 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1 Dose Escalation Cohort 1 | Phase 1 Dose Escalation Cohort 2 | Phase 1 Dose Escalation Cohort 3 | Phase 1 Dose Escalation Cohort 4 | Phase 1 Dose Escalation Cohort 5 | Phase 2 Dose Confirmation | Phase 2 Fixed-Dose Combination | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 1 | 0 | 2 | 3 | 6 |
| Not Hispanic or Latino | 7 | 6 | 5 | 5 | 18 | 46 | 26 | 113 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 1 | 2 | 1 | 5 |
| Race (NIH/OMB)(Participants) | Phase 1 Dose Escalation Cohort 1 | Phase 1 Dose Escalation Cohort 2 | Phase 1 Dose Escalation Cohort 3 | Phase 1 Dose Escalation Cohort 4 | Phase 1 Dose Escalation Cohort 5 | Phase 2 Dose Confirmation | Phase 2 Fixed-Dose Combination | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 1 | 1 | 2 | 0 | 5 |
| White | 6 | 6 | 5 | 5 | 18 | 46 | 28 | 114 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 0 | 1 | 2 | 4 |
| Region of Enrollment(participants) | Phase 1 Dose Escalation Cohort 1 | Phase 1 Dose Escalation Cohort 2 | Phase 1 Dose Escalation Cohort 3 | Phase 1 Dose Escalation Cohort 4 | Phase 1 Dose Escalation Cohort 5 | Phase 2 Dose Confirmation | Phase 2 Fixed-Dose Combination | Total |
|---|---|---|---|---|---|---|---|---|
| Canada | 0 | 0 | 0 | 0 | 0 | 8 | 8 | 16 |
| United States | 7 | 6 | 6 | 6 | 19 | 42 | 22 | 108 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Oct 2014 to primary completion in Jun 2018, 43 months.
Results were first posted in Oct 2020, 2 years 4 months after primary completion. A results delay was requested in Oct 2019.
Of 41 industry-sponsored phase 1/2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 78 months of starting (the median), counting those still running; a quarter within 56 and three quarters within 91. This study's 43 months is below that.
Counting every sponsor, half of 109 studies reached it within 78 months; a quarter within 49 and three quarters within 110.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Decitabine